Plixorafenib not checked
Fore Biotherapeutics · FORE8394 · PLX8394
FollowEvery change as it happens, and a Monday email
Trials
1 active
3 in total · 1 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-rafenib: Raf kinase inhibitors WHO name stem
- Tested for
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Main trialPhase 2
- “The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors, including rare BRAF V600E-mutated solid tumors, including anaplastic thyroid, ovarian, cholangiocarcinoma or other rare cancers.”In the company’s words, NCT05503797 on ClinicalTrials.gov
- Other names
- FORE8394 · PLX8394
Other drugs for HGG
- 5-Aminolevulinic Acid Hydrochloride PowderLee's Pharmaceutical Limited · Phase 3
- DordaviproneJazz Pharmaceuticals · Phase 3
- 131I-IPATelix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- SafusidenibNuvation Bio · Phase 3
- Cerebraca waferEverfront Biotech Co., Ltd. · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
Coming up1
- 31 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Dec 2027 | A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | |
| Phase 1/2Completed | 12 Jul 2024 | A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors | |
| Phase 1Completed | 22 Dec 2024 | A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026